A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents

(2009) T Sánchez-Pérez et al.   CELL DEATH AND DIFFERENTIATION

CYT997 Causes apoptosis in human multiple myeloma

(2009) Katherine Monaghan et al.   INVESTIGATIONAL NEW DRUGS

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

(2008) C. Gridelli et al.   ONCOLOGIST

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

(2007) M. Chatterjee et al.   BLOOD